Inmune Bio Inc. (INMB)
NASDAQ (CM) NASDAQ (CM) Primary 
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment
INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis amid regulatory alignment and a $67M market cap. Ebstrocel offers systemic itch reduction, differentiating it from competitors like KRYS's Vyjuvek, and is positioned for UK, EU, and US regulatory filings by early 2027. Regulatory milestones may include upcoming filings for approval, and the initiation of a confirmatory Phase 3 trial.
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
INmune Bio Q2 Earnings Call Highlights
INmune Bio NASDAQ: INMB outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026, while reporting a narrower second-quarter net loss and cash runway into the second quarter of 2027.
INmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks Transcript
INmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks Transcript
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript
INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
INmune Bio (INMB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript
INmune Bio, Inc. ( INMB ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Daniel Carlson David Moss - President, CEO, Treasurer, Secretary & Director Mark Lowdell - Chief Scientific Officer & Chief Manufacturing Officer CJ Barnum Cory Ellspermann - Interim Chief Financial Officer Conference Call Participants Denis Reznik - Raymond James Ltd., Research Division Jason Mccarthy - Maxim Group LLC, Research Division Presentation Operator " Daniel Carlson " David Moss President, CEO, Treasurer, Secretary & Director " Mark Lowdell Chief Scientific Officer & Chief Manufacturing Officer " CJ Barnum " Cory Ellspermann Interim Chief Financial Officer " Denis Reznik Raymond James Ltd.
INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Christopher Barnum - Corporate Participant Daniel Carlson - Corporate Participant David J. Moss - CFO, Treasurer & Secretary Mark William Lowdell - Chief Scientific Officer & Chief Manufacturing Officer Raymond Joseph Tesi - Co-Founder, President, CEO, Chief Medical Officer & Chairman Conference Call Participants Boris Tolkachev - Freedom Broker, Research Division Denis Reznik - Raymond James Ltd.
INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's
INmune Bio's XPro missed its Phase II primary endpoint, but subgroup data and safety profile suggest potential for targeted Alzheimer's patients with neuroinflammation. Despite the setback, I see significant upside from XPro and CORDStrom, with blockbuster potential if approved, given INMB's tiny current market cap. Risks include uncertain XPro efficacy, need for more capital, and dilution; I maintain a 2/5 conviction rating and keep INMB in my speculative portfolio.
INmune Bio shares tumble as Alzheimer's drug falls short in mid-stage trial
INmune Bio Inc (NASDAQ:INMB) shares plummeted almost 60% following disappointing results from a Phase 2 clinical trial of its experimental Alzheimer's drug, XPro. The drug failed to meet the primary cognitive endpoint in the overall intent-to-treat population, meaning it did not significantly improve cognitive function over six months compared to placebo in early Alzheimer's patients.
